Host |
Rabbit |
Klon |
EP25 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Colon, Colon adenocarcinoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
A synthetic peptide corresponding to residues near the C-term of human CDX-2 protein |
Lokalisation |
Nucleus |
CDX-2
|
Diagnostic Biosystems |
EP25 |
0.5 ml |
Concentrate |
CE/IVD |
RMAB059-05 |
-
|
Host |
Rabbit |
Klon |
EP25 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Colon, Colon adenocarcinoma |
Isotyp |
Rabbit IgG |
Verdünnung |
A synthetic peptide corresponding to residues near the C-term of human CDX-2 protein |
Lokalisation |
Nucleus |
CDX-2
|
Diagnostic Biosystems |
EP25 |
6 ml |
Ready-to-use |
CE/IVD |
RMPD059 |
-
|
Host |
Rabbit |
Klon |
ZR215 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Normal colon or colon adenocarcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 |
Verdünnung |
Recombinant human full-length CDX2 protein |
Lokalisation |
Nucleus |
CDX-2
|
Zeta Corporation |
ZR215 |
1.0 ml |
Concentrate |
CE/IVD |
Z2494RL |
-
|
Host |
Rabbit |
Klon |
ZR215 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Normal colon or colon adenocarcinoma |
Verdünnung |
- |
Isotyp |
IgG1 |
Verdünnung |
Recombinant human full-length CDX2 protein |
Lokalisation |
Nucleus |
CDX-2
|
Zeta Corporation |
ZR215 |
7 ml |
Ready-to-use |
CE/IVD |
Z2494RP |
-
|
Host |
Rabbit |
Klon |
ZR215 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Normal colon or colon adenocarcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 |
Verdünnung |
Recombinant human full-length CDX2 protein |
Lokalisation |
Nucleus |
CDX-2
|
Zeta Corporation |
ZR215 |
0.5 ml |
Concentrate |
CE/IVD |
Z2494RS |
-
|
Host |
Rabbit |
Klon |
ZR215 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Normal colon or colon adenocarcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 |
Verdünnung |
Recombinant human full-length CDX2 protein |
Lokalisation |
Nucleus |
CDX-2
|
Zeta Corporation |
ZR215 |
0.1 ml |
Concentrate |
CE/IVD |
Z2494RT |
-
|
Host |
Mouse + Rabbit |
Klon |
CDX2-88 + EP86 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Normal colon or colon cancer |
Verdünnung |
- |
Isotyp |
Mouse IgG1 + Rabbit IgG |
Lokalisation |
Nuclear and cytoplasmic/cell membrane |
CDX-2 (M) + CDH17 (RM)
|
Biocare Medical |
CDX2-88 + EP86 |
6 ml |
Ready-to-use |
CE/IVD |
API3135DSAA |
-
|
Host |
Mouse+Rabbit |
Klon |
CDX2-88 + BC1 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Colon cancer, breast cancer |
Verdünnung |
- |
Isotyp |
Mouse IgG1 + Rabbit IgG |
Lokalisation |
Nuclear and cytoplasmic |
CDX-2 + Cytokeratin 7
|
Biocare Medical |
CDX2-88 + BC1 |
6 ml |
Ready-to-use |
CE/IVD |
PM367DSAA |
-
|
Host |
Mouse+Rabbit |
Klon |
CDX2-88 + BC1 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Colon cancer, breast cancer |
Verdünnung |
- |
Isotyp |
Mouse IgG1 + Rabbit IgG |
Lokalisation |
Nuclear and cytoplasmic |
CDX-2 + Cytokeratin 7
|
Biocare Medical |
CDX2-88 + BC1 |
25 ml |
Ready-to-use |
CE/IVD |
PM367DSH |
-
|
Host |
Mouse |
Klon |
CEA31 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Colon carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Human colon carcinoma extract |
Lokalisation |
Cytoplasm and luminal Cell membrane |
CEA-M
|
Zeta Corporation |
CEA31 |
1.0 ml |
Concentrate |
CE/IVD |
Z2100ML |
-
|
Host |
Mouse |
Klon |
CEA31 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Colon carcinoma. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Human colon carcinoma extract |
Lokalisation |
Cytoplasm and luminal Cell membrane |
CEA-M
|
Zeta Corporation |
CEA31 |
7 ml |
Ready-to-use |
CE/IVD |
Z2100MP |
-
|
Host |
Mouse |
Klon |
CEA31 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Colon carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Human colon carcinoma extract |
Lokalisation |
Cytoplasm and luminal Cell membrane |
CEA-M
|
Zeta Corporation |
CEA31 |
0.5 ml |
Concentrate |
CE/IVD |
Z2100MS |
-
|
Host |
Mouse |
Klon |
CEA31 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Colon carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Human colon carcinoma extract |
Lokalisation |
Cytoplasm and luminal Cell membrane |
CEA-M
|
Zeta Corporation |
CEA31 |
0.1 ml |
Concentrate |
CE/IVD |
Z2100MT |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Colon carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Human colon carcinoma extract |
Lokalisation |
Cytoplasm and luminal Cell membrane |
CEA-P
|
Zeta Corporation |
polyclonal |
1.0 ml |
Concentrate |
CE/IVD |
Z2565RL |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Colon carcinoma |
Verdünnung |
- |
Isotyp |
IgG |
Verdünnung |
Human colon carcinoma extract |
Lokalisation |
Cytoplasm and luminal Cell membrane |
CEA-P
|
Zeta Corporation |
polyclonal |
7 ml |
Ready-to-use |
CE/IVD |
Z2565RP |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Colon carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Human colon carcinoma extract |
Lokalisation |
Cytoplasm and luminal Cell membrane |
CEA-P
|
Zeta Corporation |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
Z2565RS |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Colon carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Human colon carcinoma extract |
Lokalisation |
Cytoplasm and luminal Cell membrane |
CEA-P
|
Zeta Corporation |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
Z2565RT |
-
|
Host |
Rabbit |
Klon |
DBRRM2.85 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Colon Carcinoma |
Verdünnung |
1:100-1:200 |
Isotyp |
IgG kappa |
Verdünnung |
Recombinant human CEA protein fragment |
Lokalisation |
Cell Surface |
CEACAM5
|
Diagnostic Biosystems |
DBRRM2.85 |
1 ml |
Concentrate |
Übergangsfrist |
RMAB118R |
-
|
Host |
Rabbit |
Klon |
DBRRM2.85 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Colon Carcinoma |
Verdünnung |
1:100-1:200 |
Isotyp |
IgG kappa |
Verdünnung |
Recombinant human CEA protein fragment |
Lokalisation |
Cell Surface |
CEACAM5
|
Diagnostic Biosystems |
DBRRM2.85 |
0.1 ml |
Concentrate |
Übergangsfrist |
RMAB118R-01 |
-
|
Host |
Rabbit |
Klon |
DBRRM2.85 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Colon Carcinoma |
Verdünnung |
1:100-1:200 |
Isotyp |
IgG kappa |
Verdünnung |
Recombinant human CEA protein fragment |
Lokalisation |
Cell Surface |
CEACAM5
|
Diagnostic Biosystems |
DBRRM2.85 |
0.5 ml |
Concentrate |
Übergangsfrist |
RMAB118R-05 |
-
|
Host |
Rabbit |
Klon |
DBRRM2.85 |
Format |
ready-to-use |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Colon Carcinoma |
Verdünnung |
--- |
Isotyp |
IgG kappa |
Verdünnung |
Recombinant human CEA protein fragment |
Lokalisation |
Cell Surface |
CEACAM5
|
Diagnostic Biosystems |
DBRRM2.85 |
6 ml |
ready-to-use |
Übergangsfrist |
RMPD118R |
-
|
Host |
Rabbit |
Klon |
ZR370 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
HIER or PIER |
Positivkontrolle |
Colon Carcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Rabbit IgG |
Verdünnung |
Recombinant full-length human CEA protein |
Lokalisation |
Cytoplasmic and luminal membrane |
CEACAM5
|
Zeta Corporation |
ZR370 |
1 ml |
Concentrate |
CE/IVD |
Z2661RL |
-
|
Host |
Rabbit |
Klon |
ZR370 |
Format |
ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
HIER or PIER |
Positivkontrolle |
Colon Carcinoma |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Verdünnung |
Recombinant full-length human CEA protein |
Lokalisation |
Cytoplasmic and luminal membrane |
CEACAM5
|
Zeta Corporation |
ZR370 |
7 ml |
ready-to-use |
CE/IVD |
Z2661RP |
-
|
Host |
Rabbit |
Klon |
ZR370 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
HIER or PIER |
Positivkontrolle |
Colon Carcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Rabbit IgG |
Verdünnung |
Recombinant full-length human CEA protein |
Lokalisation |
Cytoplasmic and luminal membrane |
CEACAM5
|
Zeta Corporation |
ZR370 |
0.5 ml |
Concentrate |
CE/IVD |
Z2661RS |
-
|
Host |
Rabbit |
Klon |
ZR370 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
HIER or PIER |
Positivkontrolle |
Colon Carcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Rabbit IgG |
Verdünnung |
Recombinant full-length human CEA protein |
Lokalisation |
Cytoplasmic and luminal membrane |
CEACAM5
|
Zeta Corporation |
ZR370 |
0.1 ml |
Concentrate |
CE/IVD |
Z2661RT |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Trypsin |
Positivkontrolle |
Small Intestine |
Verdünnung |
1:200 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide sulfated cholecystokinin (26-33) amide (sulfated CCK-8). |
Lokalisation |
Cytoplasmic, Lumenal Membrane |
Cholecystokinin (26-33)
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Concentrate |
RUO |
503-4514 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Purified |
Methode |
EL, IP |
Isotyp |
Rabbit IgG |
Verdünnung |
Purified Choleragenoid |
Cholera Toxin (beta Subunit)
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Purified |
RUO |
603-1886 |
-
|
Host |
Mouse |
Klon |
LK2H10+PHE5 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
CC1 |
Positivkontrolle |
Pancreas, Adrenal gland |
Verdünnung |
- |
Isotyp |
Mouse IgG1+ Mouse IgG1 |
Lokalisation |
Cytoplasm |
Chromogranin A
|
Biocare Medical |
LK2H10+PHE5 |
6 ml |
Ready-to-use |
CE/IVD |
AVI010G |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Pancreas |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
Chromogranin A
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
RP008 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Pancreas |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
Chromogranin A
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
RP008-01 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Pancreas |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
Chromogranin A
|
Diagnostic Biosystems |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
RP008-05 |
-
|
Host |
Monospecific Mouse |
Klon |
ZM12 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Pancreas or neuroendocrine tumor. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant human Chromogranin A protein |
Lokalisation |
Cytoplasm |
Chromogranin A
|
Zeta Corporation |
ZM12 |
1 ml |
Concentrate |
CE/IVD |
Z2347ML |
-
|
Host |
Monospecific Mouse |
Klon |
ZM12 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Pancreas or neuroendocrine tumor. |
Verdünnung |
- |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant human Chromogranin A protein |
Lokalisation |
Cytoplasm |
Chromogranin A
|
Zeta Corporation |
ZM12 |
7 ml |
Ready-to-use |
CE/IVD |
Z2347MP |
-
|
Host |
Monospecific Mouse |
Klon |
ZM12 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Pancreas or neuroendocrine tumor. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant human Chromogranin A protein |
Lokalisation |
Cytoplasm |
Chromogranin A
|
Zeta Corporation |
ZM12 |
0.5 ml |
Concentrate |
CE/IVD |
Z2347MS |
-
|
Host |
Monospecific Mouse |
Klon |
ZM12 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Pancreas or neuroendocrine tumor. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant human Chromogranin A protein |
Lokalisation |
Cytoplasm |
Chromogranin A
|
Zeta Corporation |
ZM12 |
0.1 ml |
Concentrate |
CE/IVD |
Z2347MT |
-
|
Host |
Mouse |
Klon |
4E1 |
Format |
Purified |
Methode |
F, P, WB, EL |
Isotyp |
Mouse IgG3 |
Verdünnung |
Native pancreatic |
Chymotrypsin
|
Zytomed Systems GmbH |
4E1 |
200 µg |
Purified |
RUO |
603-1908 |
-
|
Host |
Mouse+Rabbit |
Klon |
34ßE12+4A4+13H4 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Reveal modified Citrate pH 6.0 or pH 6.2 |
Positivkontrolle |
Prostate intraepithelial neoplasia PIN |
Verdünnung |
- |
Isotyp |
MouseIgG1/kappa+IgG2a+RabbitIgG |
Lokalisation |
Cytoplasmic and nuclear |
CK HMW + p63 + AMACR (RM)
|
Biocare Medical |
34ßE12+4A4+13H4 |
6 ml |
Ready-to-use |
CE/IVD |
API3154DSAA |
-
|
Host |
Mouse+Rabbit |
Klon |
34ßE12+4A4+13H4 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Reveal modified Citrate pH 6.0 or pH 6.2 |
Positivkontrolle |
Prostate intraepithelial neoplasia PIN |
Verdünnung |
- |
Isotyp |
MouseIgG1/kappa+IgG2a+RabbitIgG |
Lokalisation |
Cytoplasmic and nuclear |
CK HMW + p63 + AMACR (RM)
|
Biocare Medical |
34ßE12+4A4+13H4 |
25 ml |
Ready-to-use |
CE/IVD |
API3154DSH |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Skin, Breast Carcinoma |
Verdünnung |
1:200 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide derived from the C-terminus of human Claudin-1. |
Lokalisation |
Cell Membrane on Skin, Cytoplasmic/Nuclear on Mamma |
Claudin 1
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Concentrate |
RUO |
503-3414 |
-
|
Host |
Rabbit |
Klon |
SP128 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Liver, hepatocellular carcinoma |
Verdünnung |
1:200 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide corresponding to the C-terminus of human claudin-1 protein |
Lokalisation |
Cell Membrane |
Claudin 1
|
Zytomed Systems GmbH |
SP128 |
0.1 ml |
Concentrate |
RUO |
503-4280 |
-
|
Host |
Rabbit |
Klon |
SP128 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Liver, liver carcinoma |
Verdünnung |
1:200 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide corresponding to the C-terminus of human claudin-1 protein |
Lokalisation |
Cell Membrane |
Claudin 1
|
Zytomed Systems GmbH |
SP128 |
0.5 ml |
Concentrate |
RUO |
503-4282 |
-
|
Host |
Rabbit |
Klon |
SP128 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Liver, liver carcinoma |
Verdünnung |
1:200 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide corresponding to the C-terminus of human claudin-1 protein |
Lokalisation |
Cell Membrane |
Claudin 1
|
Zytomed Systems GmbH |
SP128 |
1 ml |
Concentrate |
RUO |
503-4284 |
-
|
Host |
Mouse |
Klon |
3E2C1 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Colon carcinoma or breast carcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Mouse IgG1 |
Verdünnung |
Synthetic peptide corresponding to a 22 amino acid sequence derived from the C-terminal region of human Claudin-4 |
Lokalisation |
Cell membrane |
Claudin 4
|
Biocare Medical |
3E2C1 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3121A |
-
|
Host |
Mouse |
Klon |
3E2C1 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Colon carcinoma or breast carcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Mouse IgG1 |
Verdünnung |
Synthetic peptide corresponding to a 22 amino acid sequence derived from the C-terminal region of human Claudin-4 |
Lokalisation |
Cell membrane |
Claudin 4
|
Biocare Medical |
3E2C1 |
0.5 ml |
Concentrate |
CE/IVD |
ACI3121B |
-
|
Host |
Mouse |
Klon |
3E2C1 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Colon carcinoma or breast carcinoma |
Verdünnung |
- |
Isotyp |
Mouse IgG1 |
Verdünnung |
Synthetic peptide corresponding to a 22 amino acid sequence derived from the C-terminal region of human Claudin-4 |
Lokalisation |
Cell membrane |
Claudin 4
|
Biocare Medical |
3E2C1 |
6 ml |
Ready-to-use |
CE/IVD |
API3121AA |
-
|
Host |
Rabbit |
Klon |
DBRRM1.82 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Stomach |
Verdünnung |
1:50-1:100 |
Isotyp |
IgG kappa |
Verdünnung |
Recombinant human Claudin18.2protein fragment (around aa 1-100) |
Lokalisation |
Cell membrane |
Claudin 18.2
|
Diagnostic Biosystems |
DBRRM1.82 |
1 ml |
Concentrate |
Übergangsfrist |
RMAB116R |
-
|
Host |
Rabbit |
Klon |
DBRRM1.82 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Stomach |
Verdünnung |
1:50-1:100 |
Isotyp |
IgG kappa |
Verdünnung |
Recombinant human Claudin18.2protein fragment (around aa 1-100) |
Lokalisation |
Cell membrane |
Claudin 18.2
|
Diagnostic Biosystems |
DBRRM1.82 |
0.1 ml |
Concentrate |
Übergangsfrist |
RMAB116R-01 |
-
|
Host |
Rabbit |
Klon |
DBRRM1.82 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Stomach |
Verdünnung |
1:50-1:100 |
Isotyp |
IgG kappa |
Verdünnung |
Recombinant human Claudin18.2protein fragment (around aa 1-100) |
Lokalisation |
Cell membrane |
Claudin 18.2
|
Diagnostic Biosystems |
DBRRM1.82 |
0.5 ml |
Concentrate |
Übergangsfrist |
RMAB116R-05 |
-
|
Host |
Rabbit |
Klon |
DBRRM1.82 |
Format |
ready-to-use |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Stomach |
Verdünnung |
--- |
Isotyp |
IgG kappa |
Verdünnung |
Recombinant human Claudin18.2protein fragment (around aa 1-100) |
Lokalisation |
Cell membrane |
Claudin 18.2
|
Diagnostic Biosystems |
DBRRM1.82 |
6 ml |
ready-to-use |
Übergangsfrist |
RMPD116R |
-
|
Host |
Rabbit |
Klon |
ZR451 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Carcinomas |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment (around aa1-100) of human Claudin18.2 protein |
Lokalisation |
Membrane |
Claudin 18.2
|
Zeta Corporation |
ZR451 |
1 ml |
Concentrate |
RUO |
Z2807RL-R |
-
|